share_log

BRIEF-Novo Nordisk Announces Impact From Volume Based Procurement For Insulin In China

reuters ·  2021/11/26 01:10

Nov 26 (Reuters) - Novo Nordisk A/S NOVOb.CO :

* REG-NOVO NORDISK ANNOUNCES IMPACT FROM VOLUME BASED PROCUREMENT FOR INSULIN IN CHINA

* WILL PROVIDE FINANCIAL OUTLOOK FOR 2022 IN CONNECTION WITH ANNOUNCEMENT OF FULL-YEAR 2021 RESULTS ON 2 FEBRUARY 2022.

* CURRENTLY EXPECTS AN ESTIMATED NEGATIVE IMPACT ON GLOBAL SALES GROWTH OF AROUND 3% IN 2022

* REDUCED PRICES AND REDUCED VOLUMES OF INSULIN SOLD IN CHINA.

* VBP FOR INSULIN IS EXPECTED TO BE IMPLEMENTED DURING FIRST HALF OF 2022

Source text for Eikon: ID:nGNE6sgxcR Further company coverage: NOVOb.CO

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする